Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects

TY - JOUR

T1 - Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects

AU - Kappelle, Paul J W H

AU - Lambert, Gilles

AU - Dahlbäck, Björn

AU - Nielsen, Lars Bo

AU - Dullaart, Robin P F

N1 - Copyright © 2010. Published by Elsevier Ireland Ltd.

PY - 2011/2

Y1 - 2011/2

N2 - Purpose: Apolipoprotein M (apoM) retards atherosclerosis development in murine models, and may be regulated by pathways involved in LDL metabolism. Proprotein convertase subtilisin-kexin type 9 (PCSK9) plays a key role in LDL receptor processing. We determined the extent to which plasma apoM is related to PCSK9 levels in subjects with varying degrees of obesity. Methods: We sought correlations between plasma apoM and PCSK9, measured using recently developed ELISAs, in 79 non-diabetic subjects. Results: ApoM and PCSK9 levels were both correlated positively with total cholesterol, non-HDL cholesterol, LDL cholesterol and apoB (p< 0.05 to p< 0.001). ApoM correlated positively with PCSK9 in lean individuals (n = 37, r = 0.337, P = 0.041), but not in overweight subjects (n = 32, r = 0.125, P = 0.50) and in obese subjects (n = 10, r = -0.055, P = 0.88). Conclusions: The PCSK9 pathway may contribute to plasma apoM regulation in humans. The influence of PCSK9 on circulating apoM appears to be modified by adiposity.

AB - Purpose: Apolipoprotein M (apoM) retards atherosclerosis development in murine models, and may be regulated by pathways involved in LDL metabolism. Proprotein convertase subtilisin-kexin type 9 (PCSK9) plays a key role in LDL receptor processing. We determined the extent to which plasma apoM is related to PCSK9 levels in subjects with varying degrees of obesity. Methods: We sought correlations between plasma apoM and PCSK9, measured using recently developed ELISAs, in 79 non-diabetic subjects. Results: ApoM and PCSK9 levels were both correlated positively with total cholesterol, non-HDL cholesterol, LDL cholesterol and apoB (p< 0.05 to p< 0.001). ApoM correlated positively with PCSK9 in lean individuals (n = 37, r = 0.337, P = 0.041), but not in overweight subjects (n = 32, r = 0.125, P = 0.50) and in obese subjects (n = 10, r = -0.055, P = 0.88). Conclusions: The PCSK9 pathway may contribute to plasma apoM regulation in humans. The influence of PCSK9 on circulating apoM appears to be modified by adiposity.

KW - Adiposity

KW - Aged

KW - Apolipoproteins

KW - Apolipoproteins B

KW - Biological Markers

KW - Body Mass Index

KW - Cholesterol

KW - Cholesterol, LDL

KW - Enzyme-Linked Immunosorbent Assay

KW - Humans

KW - Lipocalins

KW - Middle Aged

KW - Netherlands

KW - Obesity

KW - Overweight

KW - Regression Analysis

KW - Serine Endopeptidases

U2 - 10.1016/j.atherosclerosis.2010.10.041

DO - 10.1016/j.atherosclerosis.2010.10.041

M3 - Journal article

C2 - 21122852

SN - 0021-9150

VL - 214

SP - 492

EP - 494

JO - Atherosclerosis

JF - Atherosclerosis

IS - 2

ER -